OS Therapies Management
Management criteria checks 4/4
OS Therapies' CEO is Paul Romness, appointed in Apr 2018, has a tenure of 6.75 years. total yearly compensation is $360.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 10.58% of the company’s shares, worth $9.62M. The average tenure of the management team and the board of directors is 2 years and 4.1 years respectively.
Key information
Paul Romness
Chief executive officer
US$360.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 10.6% |
| Management average tenure | 2yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$7m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$360k | US$360k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$7m |
| Dec 31 2022 | US$360k | US$360k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$360k | US$360k | -US$8m |
Compensation vs Market: Paul's total compensation ($USD360.00K) is below average for companies of similar size in the US market ($USD649.25K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Romness (58 yo)
6.8yrs
Tenure
US$360,000
Compensation
Mr. Paul A. Romness, MPH, is Founder, President, Chief Executive Officer and Director of OS Therapies Inc. since April 2018 and as its Chairman from October 2024. Prior to founding OS Therapies Inc., Mr. R...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.8yrs | US$360.00k | 10.58% $ 9.6m | |
| Chief Medical Officer & Chief Scientific Officer | 5.3yrs | US$300.00k | 0.94% $ 856.0k | |
| Chief Financial Officer | 1.5yrs | no data | 0.47% $ 428.0k | |
| Chief of Staff | 2yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
2.0yrs
Average Tenure
59.5yo
Average Age
Experienced Management: OSTX's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.8yrs | US$360.00k | 10.58% $ 9.6m | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.1yrs | US$40.00 | 0.094% $ 85.6k | |
| Member of Antibody Drug Conjugate (ADC) Advisory Board | no data | US$180.00k | no data | |
| Independent Director | 4.1yrs | US$40.00 | 0.094% $ 85.6k | |
| Member of Patient Advocacy Advisory Board | less than a year | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
51yo
Average Age
Experienced Board: OSTX's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:14 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OS Therapies Incorporated is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Jason Kolbert | D. Boral Capital LLC. |
| Jason McCarthy | Maxim Group |